Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasminogen activators are serine protease enzymes that convert plasminogen to plasmin, initiating fibrinolysis and regulating blood clot dissolution. Key types include tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). These enzymes play crucial roles in hemostasis, tissue remodeling, cell migration, and synaptic plasticity. Recombinant tPA is used therapeutically for thrombolysis, but excessive or insufficient activity can lead to bleeding complications or increased thrombosis risk, respectively.
Catalyzes the conversion of plasminogen to plasmin, which degrades fibrin in blood clots.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasminogen Activator Enzyme (PA).